about
Linkage of clinical trial and administrative data: a survey of cancer patient preferences.An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.Accrual of adolescents and young adults with cancer to clinical trials.Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial.Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.Volunteer counsellors for supporting breast feeding: support for breast feeding must be proactive.Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.Latency of onset of de novo myelodysplastic syndromesHepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectivenessA retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorlyEffect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup/>A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma
P50
Q33840128-202E9106-2501-46A6-950D-46E3F95FE9B6Q35016354-5BD53178-4746-4AB2-BF8C-4DB5EBB3ED59Q36658848-A28AE3B5-8C0E-4FA4-B75A-5272571B46B1Q36807905-EEADBD4A-BF48-44DA-A336-A34A43D3169CQ37383554-01094EF0-882B-47D3-A795-3829230E056CQ38383331-3934E32A-5369-49E9-AF5C-FE224CB1AD21Q38642477-E9477488-69E5-41A2-A414-3B76CA91313EQ40575926-A9361581-EB8F-4F23-AF6B-2CAB47FBEB90Q41080351-0D21462D-ADF7-485C-B666-FC81D39B5071Q43155203-FB696DCC-3351-4E49-A796-FBA7BAB91817Q48064229-EE53882F-C15C-4A6C-B813-BF34E721198FQ48166494-4F5F750F-FF3B-46F8-BD7F-45A65B37245AQ48650246-2F3AA234-B74F-4BE7-BDD5-02DB73A85E96Q53006177-EA18EFAA-1B8A-41C9-B66A-05D43B4B968DQ53817434-A300A9DD-D4EC-4627-9575-DDF19C867A34Q80974685-1A807D69-DA1D-4B2A-BFB7-8D726F363ABBQ84791312-CFE3C24D-C135-4995-9B99-BDA5916BE91DQ86360813-71D92C9A-7EDB-418F-ABDB-B59BA1B5F36FQ87594437-E540E67F-E36E-496B-9EE6-2C01FAFA8A0DQ87739457-68ADEF36-6C2A-4C5F-816E-249F3109F60E
P50
description
researcher ORCID ID = 0000-0003-4581-3390
@en
wetenschapper
@nl
name
Annette E Hay
@ast
Annette E Hay
@en
Annette E Hay
@nl
type
label
Annette E Hay
@ast
Annette E Hay
@en
Annette E Hay
@nl
prefLabel
Annette E Hay
@ast
Annette E Hay
@en
Annette E Hay
@nl
P106
P31
P496
0000-0003-4581-3390